Search Results - "van der Veen, Elly L"

Clinical-grade N-(4-[18F]fluorobenzoyl)-interleukin-2 for PET imaging of activated T-cells in humans by van der Veen, Elly L., Antunes, Inês F., Maarsingh, Petra, Hessels-Scheper, Janet, Zijlma, Rolf, Boersma, Hendrikus H., Jorritsma-Smit, Annelies, Hospers, Geke A. P., de Vries, Elisabeth G. E., Lub-de Hooge, Marjolijn N., de Vries, Erik F. J.

“…Background Molecular imaging of immune cells might be a potential tool for response prediction, treatment evaluation and patient selection in inflammatory…”
Get full text

Interleukin-2 PET imaging in patients with metastatic melanoma before and during immune checkpoint inhibitor therapy by van de Donk, Pim P., Wind, Thijs T., Hooiveld-Noeken, Jahlisa S., van der Veen, Elly L., Glaudemans, Andor W. J. M., Diepstra, Arjan, Jalving, Mathilde, de Vries, Elisabeth G. E., de Vries, Erik F. J., Hospers, Geke A. P.

“…Purpose Immune checkpoint inhibitors can induce a T cell–mediated anti-tumor immune response in patients with melanoma. Visualizing T cell activity using…”
Get full text

PET/CT Imaging of 89Zr-N-sucDf-Pembrolizumab in Healthy Cynomolgus Monkeys by Li, Wenping, Wang, Yuchuan, Rubins, Daniel, Bennacef, Idriss, Holahan, Marie, Haley, Hyking, Purcell, Mona, Gantert, Liza, Hseih, SuChun, Judo, Michael, Seghezzi, Wolfgang, Zhang, Shuli, van der Veen, Elly L., Lub-de Hooge, Marjolijn N., de Vries, Elisabeth G.E., Evelhoch, Jeffrey L., Klimas, Michael, Hostetler, Eric D.

“…Purpose Programmed cell death-1 receptor (PD-1) and its ligand (PD-L1) are the targets for immunotherapy in many cancer types. Although PD-1 blockade has…”
Get full text

89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer by Bensch, Frederike, van der Veen, Elly L., Lub-de Hooge, Marjolijn N., Jorritsma-Smit, Annelies, Boellaard, Ronald, Kok, Iris C., Oosting, Sjoukje F., Schröder, Carolina P., Hiltermann, T. Jeroen N., van der Wekken, Anthonie J., Groen, Harry J. M., Kwee, Thomas C., Elias, Sjoerd G., Gietema, Jourik A., Bohorquez, Sandra Sanabria, de Crespigny, Alex, Williams, Simon-Peter, Mancao, Christoph, Brouwers, Adrienne H., Fine, Bernard M., de Vries, Elisabeth G. E.

“…Programmed cell death protein-1/ligand-1 (PD-1/PD-L1) blockade is effective in a subset of patients with several tumor types, but predicting patient benefit…”
Get full text

Development and Evaluation of Interleukin-2-Derived Radiotracers for PET Imaging of T Cells in Mice by van der Veen, Elly L, Suurs, Frans V, Cleeren, Frederik, Bormans, Guy, Elsinga, Philip H, Hospers, Geke A P, Lub-de Hooge, Marjolijn N, de Vries, Elisabeth G E, de Vries, Erik F J, Antunes, Inês F

“…Recently, -(4- F-fluorobenzoyl)-interleukin-2 ( F-FB-IL2) was introduced as a PET tracer for T cell imaging. However, production is complex and time-consuming…”
Get full text

Molecular imaging to enlighten cancer immunotherapies and underlying involved processes by van der Veen, Elly L., Bensch, Frederike, Glaudemans, Andor W.J.M., Lub-de Hooge, Marjolijn N., de Vries, Elisabeth G.E.

“…•Molecular imaging enables visualization of important components involved in immunotherapy.•Radiopharmaceuticals can target tumor cells, immune cells and…”
Get full text

89 Zr-pembrolizumab biodistribution is influenced by PD-1-mediated uptake in lymphoid organs by van der Veen, Elly L, Giesen, Danique, Pot-de Jong, Linda, Jorritsma-Smit, Annelies, De Vries, Elisabeth G E, Lub-de Hooge, Marjolijn N

“…To better predict response to immune checkpoint therapy and toxicity in healthy tissues, insight in the in vivo behavior of immune checkpoint targeting…”
Get full text

Molecular Imaging of PD-L1 Expression and Dynamics with the Adnectin-Based PET Tracer 18 F-BMS-986192 by Stutvoet, Thijs S, van der Veen, Elly L, Kol, Arjan, Antunes, Inês F, de Vries, Erik F J, Hospers, Geke A P, de Vries, Elisabeth G E, de Jong, Steven, Lub-de Hooge, Marjolijn N

“…F-BMS-986192, an adnectin-based human programmed cell death ligand 1 (PD-L1) tracer, was developed to noninvasively determine whole-body PD-L1 expression by…”
Get full text

Abstract 4208: Development of 18F-IL2: a PET radiotracer for imaging activated T-cells by van der Veen, Elly L., Maarsingh, Petra, Terwisscha van Scheltinga, Anton G.T., Lub-de Hooge, Marjolijn N., Hospers, Geke A.P., de Vries, Erik F.J., de Vries, Elisabeth G.E.

“…Abstract Introduction: Activation of T-cells is accompanied by a strong up-regulation of interleukin-2 (IL2) receptor (CD25). Therefore PET imaging of IL2…”
Get full text

89Zr-pembrolizumab biodistribution is influenced by PD-1-mediated uptake in lymphoid organs by van der Veen, Elly L, Giesen, Danique, Pot-de Jong, Linda, Jorritsma-Smit, Annelies, De Vries, Elisabeth G E, Lub-de Hooge, Marjolijn N

“…BackgroundTo better predict response to immune checkpoint therapy and toxicity in healthy tissues, insight in the in vivo behavior of immune checkpoint…”
Get full text

89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer by Bensch, Frederike, van der Veen, Elly L., Lub-de Hooge, Marjolijn N., Jorritsma-Smit, Annelies, Boellaard, Ronald, Kok, Iris C., Oosting, Sjoukje F., Schröder, Carolina P., Hiltermann, T. Jeroen N., van der Wekken, Anthonie J., Groen, Harry J. M., Kwee, Thomas C., Elias, Sjoerd G., Gietema, Jourik A., Bohorquez, Sandra Sanabria, de Crespigny, Alex, Williams, Simon-Peter, Mancao, Christoph, Brouwers, Adrienne H., Fine, Bernard M., de Vries, Elisabeth G. E.

Get full text

sup.89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer by Bensch, Frederike, van der Veen, Elly L, Lub-de Hooge, Marjolijn N, Jorritsma-Smit, Annelies, Boellaard, Ronald, Kok, Iris C, Oosting, Sjoukje F

“…Programmed cell death protein-1/ligand-1 (PD-1/PD-L1) blockade is effective in a subset of patients with several tumor types, but predicting patient benefit…”
Get full text

Molecular Imaging of PD-L1 Expression and Dynamics with the Adnectin-Based PET Tracer 18F-BMS-986192 by Stutvoet, Thijs S, van der Veen, Elly L, Kol, Arjan, Antunes, Inês F, de Vries, Erik FJ, Hospers, Geke AP, de Vries, Elisabeth GE, de Jong, Steven, Lub-de Hooge, Marjolijn N

“…18F-BMS-986192, an adnectin-based human programmed cell death ligand 1 (PD-L1) tracer, was developed to noninvasively determine whole-body PD-L1 expression by…”
Get full text

PET/CT Imaging of 89 Zr-N-sucDf-Pembrolizumab in Healthy Cynomolgus Monkeys by Li, Wenping, Wang, Yuchuan, Rubins, Daniel, Bennacef, Idriss, Holahan, Marie, Haley, Hyking, Purcell, Mona, Gantert, Liza, Hseih, SuChun, Judo, Michael, Seghezzi, Wolfgang, Zhang, Shuli, van der Veen, Elly L, Lub-de Hooge, Marjolijn N, de Vries, Elisabeth G E, Evelhoch, Jeffrey L, Klimas, Michael, Hostetler, Eric D

“…Programmed cell death-1 receptor (PD-1) and its ligand (PD-L1) are the targets for immunotherapy in many cancer types. Although PD-1 blockade has therapeutic…”
Get full text

89 Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer by Bensch, Frederike, van der Veen, Elly L, Lub-de Hooge, Marjolijn N, Jorritsma-Smit, Annelies, Boellaard, Ronald, Kok, Iris C, Oosting, Sjoukje F, Schröder, Carolina P, Hiltermann, T Jeroen N, van der Wekken, Anthonie J, Groen, Harry J M, Kwee, Thomas C, Elias, Sjoerd G, Gietema, Jourik A, Bohorquez, Sandra Sanabria, de Crespigny, Alex, Williams, Simon-Peter, Mancao, Christoph, Brouwers, Adrienne H, Fine, Bernard M, de Vries, Elisabeth G E

“…Programmed cell death protein-1/ligand-1 (PD-1/PD-L1) blockade is effective in a subset of patients with several tumor types, but predicting patient benefit…”
Get full text